AbCellera Biologics Financial Statements
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AbCellera Biologics revenue and earnings
In fiscal 2025, AbCellera Biologics generated $75.1 million in revenue, up 160.6% from fiscal 2024. AbCellera Biologics reported a net loss of $146.4 million, compared with a loss of $162.9 million a year earlier. Operating margin was -289.0%.
Diluted earnings per share came in at -$0.49. Over the last 5 fiscal years, ABCL's revenue has grown at a -20.3% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
AbCellera Biologics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 75.13M | 28.83M | 38.02M | 485.42M | 375.20M | 233.16M | 11.61M |
| Revenue growth (YoY) | +160.56% | -24.17% | -92.17% | +29.38% | +60.92% | +1907.88% | — |
| Operating Expenses | 292.23M | 343.60M | 275.23M | 268.91M | 170.79M | 77.12M | 15.73M |
| Research & Development | 186.83M | 167.26M | 175.66M | 107.88M | 62.06M | 29.39M | 10.11M |
| Selling, General & Admin | — | 98.27M | 89.36M | 66.75M | 48.76M | 15.75M | 4.01M |
| Operating Income | -217.10M | -314.77M | -237.21M | 216.51M | 204.41M | 156.03M | -4.12M |
| Other Income (Expense) | 39.51M | 114.37M | 63.18M | 22.59M | 14.74M | 1.80M | 1.91M |
| Pretax Income | -177.59M | -200.40M | -174.03M | 239.10M | 219.15M | 157.83M | -2.21M |
| Income Tax | -31.18M | -37.54M | -27.63M | 80.58M | 65.69M | 38.91M | — |
| Net Income | -146.41M | -162.86M | -146.40M | 158.52M | 153.46M | 118.92M | -2.21M |
| Net Income growth (YoY) | — | — | -192.35% | +3.29% | +29.05% | — | — |
| EPS (Basic) | -0.49 | -0.55 | -0.51 | 0.56 | 0.56 | 0.53 | -0.01 |
| EPS (Diluted) | -0.49 | -0.55 | -0.51 | 0.50 | 0.48 | 0.45 | -0.01 |
| Shares Outstanding (Basic) | 298.71M | 294.33M | 289.17M | 285.06M | 275.76M | 159.20M | 151.33M |
| Shares Outstanding (Diluted) | 298.71M | 294.33M | 289.17M | 314.83M | 318.29M | 263.13M | 151.33M |
| EBITDA | -198.66M | -302.23M | -212.81M | 244.35M | 218.86M | 160.87M | -2.51M |
| Operating Margin | -288.98% | -1091.69% | -623.82% | 44.60% | 54.48% | 66.92% | -35.45% |
| Net Margin | -194.88% | -564.83% | -385.00% | 32.66% | 40.90% | 51.00% | -19.04% |
This table shows 7 annual periods of AbCellera Biologics's income statement, from FY 2025 back to FY 2019, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ABCL's reporting calendar. What is a income statement?